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and kidney or liver dysfunction. These complica­
tions influence the patient’s life expectancy and 
quality of life.6,7
The characteristic hemodynamic derangement 
in Fontan circulation causing liver abnormalities 
and pathology is commonly identified as Fontan­
­associated liver disease (FALD).2,8 This can lead 
to nodular hyperplasia, cirrhosis, and hepatocel­
lular carcinoma associated with ascites, variceal 
bleeding, and encephalopathy. Moreover, it is re­
lated with higher late morbidity and mortality in 
this particular population.8-10
Recent studies have shown that elevated ve­
nous pressure (3­ to 4 ­fold in comparison with 
INTRODUCTION The Fontan procedure was first 
described over 40 years ago and still remains 
the standard surgical treatment for patients with 
a functional single ventricular heart, affecting 
35 per 100 000 newborns.1-3 It is considered one of 
the most complex congenital heart diseases. Dur­
ing the procedure, a systemic venous return is di­
rectly connected with pulmonary circulation, with­
out a subpulmonary pump.1,4,5 As a result, the cir­
culatory system is hemodynamically less efficient.
Although the Fontan procedure is associated 
with low mortality, once patients reach adulthood, 
they can develop various cardiac and extracar­
diac complications, including plastic bronchitis 
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ABSTRACT
INTRODUCTION A hemodynamic derangement in Fontan circulation causes liver pathology known as 
Fontan ‑associated liver disease. Although liver biopsy is a standard for diagnosis of liver fibrosis, non‑
invasive methods are being developed, including shear wave elastography (SWE).
OBJECTIVES We aimed to evaluate the degree of liver stiffness (LS) using SWE in patients with Fontan 
circulation in a long ‑term follow ‑up and to investigate a relationship between patient characteristics and LS.
PATIENTS AND METHODS The study included 59 patients after the Fontan procedure. Clinical examina‑
tions and laboratory tests were performed. According to the stage of LS, patients were divided into 
2 subgroups: group 1 (METAVIR stages F1 and F2) and group 2 (METAVIR stages F3 and F4). The ratio 
of aspartate transaminase to alanine transaminase, aspartate transaminase ‑to ‑platelet ratio index (APRI), 
fibrosis ‑4 (FIB ‑4) score, and Forns index were assessed.
RESULTS The median LS was 9.1 kPa (interquartile range, 3.9–18.5 kPa). Five patients (9%) demonstrated 
LS in stage F1; 14 (26%), F2; 28 (52%), F3; and 7 (13%), F4. Group 2 had significantly higher aspartate 
transaminase and γ ‑glutamyltranspeptidase levels, APRI, FIB ‑4, and Forns index, and lower platelet count 
than group 1. A canonical correlation analysis indicated that LS and thrombocytopenia were related to 
time from the Fontan procedure, age at procedure, and single ventricular ejection fraction.
CONCLUSIONS We showed that adult patients after the Fontan procedure develop liver dysfunction. 
Time from surgery, age at procedure, and single ventricular ejection fraction are related to the degree 
of LS assessed by SWE. Finally, SWE, APRI, Forns index, and FIB ‑4 score may help assess the degree 
of liver fibrosis.
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functional class, vital signs, weight, height, echo­
cardiography, and SWE.
The severity of liver disease was assessed us­
ing the Child–Pugh scale (including total bili­
rubin, albumin, international normalized ratio 
[INR] level, presence of ascites, and encephalop­
athy), VAST score (including the presence of var­
ices, ascites, splenomegaly, or thrombocytope­
nia), and Model For End ­stage Liver Disease Ex­
cluding INR (MELD ­XI). According to the stage 
of LS assessed by SWE, patients were divided 
into 2 subgroups depending on the stage of fi­
brosis: group 1 (METAVIR stage 1 or 2 [F1, F2]) 
and group 2 (METAVIR stage 3 or 4 [F3 and F4]).
The study protocol was approved by the local 
ethics committee (No. 1072.6120.110.2017). Each 
participant provided informed consent prior to 
participation in this study.
Laboratory tests The following laboratory pa­
rameters were measured: red blood cell count, 
hematocrit, hemoglobin, red blood cell dis­
tribution width, N ­terminal fragment of 
the prohormone brain natriuretic peptide (NT­
­proBNP), as well as liver function markers in­
cluding serum protein electrophoresis, ALT, AST, 
γ ­glutamyltranspeptidase (GGTP), alkaline phos­
phatase (ALP), total bilirubin level, α ­fetoprotein, 
and serologic tests for hepatitis B and C.
Furthermore, the following tests for liver fi­
brosis assessment were performed, allowing 
an estimation of several parameters calculated 
according to specific formulas: platelet count, 
AST/ALT ratio,11,19,21 APRI,19-21 FIB ­4 score,19,20 
Forns index,19,20,22,23 and MELD ­XI score.20,24,25
Echocardiography Single ventricular ejection 
fraction (SVEF) and valvular competence were 
evaluated and semiquantified by 2 experienced 
cardiologists using echocardiography (Vivid 7 GE 
Medical System, Chicago, Illinois, United States).
Abdominal ultrasonography, shear wave elastogra-
phy, and vascular Doppler Vascular Doppler and 
SWE were performed using Philips iU22 XMa­
trix Ultrasound System (Amsterdam, the Neth­
erlands) by an experienced physician. For each 
patient, 10 measurements were taken for LS es­
timation. Doppler assessments of the main por­
tal vein (MPV) and splenic vein were performed.
Statistical analysis Continuous variables were 
expressed as mean (SD) in the case of normal dis­
tribution or as median (interquartile range [IQR]) 
when the distribution was other than normal. 
Categorical variables were reported as counts 
and percentages. The conformity of continuous 
variables to the normal distribution was ana­
lyzed using the Shapiro–Wilk test. The χ2 test, 
Mann –Whitney test, t test, and Kruskal–Wal­
lis test were used where appropriate. Individu­
al parameters were calculated using the Spear­
man rank test. The factors determining LS were 
analyzed using a canonical correlation analysis. 
normal) affects portal pressure and is common 
among patients with Fontan circulation. As a con­
sequence, it can drive the activation and transfor­
mation of stellate cells into collagen ­depositing 
myofibroblasts and increase proinflammatory 
activity, leading to liver fibrosis.2,11,12 Howev­
er, the pathogenesis of FALD is different and 
more complex than in other liver diseases, such 
as chronic hepatitis.12
Although percutaneous liver biopsy is the stan­
dard method for the diagnosis and evaluation of 
liver fibrosis, noninvasive tests (including bio­
chemical tests, shear wave elastography [SWE], 
and magnetic resonance elastography) have be­
come more clinically relevant and useful, with 
good sensitivity and specificity in the detec­
tion and evaluation of the degree of liver dis­
ease among patients with various hepatic dis­
orders, including FALD. Fibrosis scores such as 
the ratio of aspartate transaminase (AST) to al­
anine transaminase (ALT) (AST/ALT ratio), AST­
­to ­platelet ratio index (APRI), Forns index, and 
fibrosis ­4 (FIB ­4) score are based on widely used 
biochemical and clinical parameters.7-9,13,14
Shear wave elastography is the most accurate 
noninvasive method for the evaluation of liver 
stiffness (LS)15,16 and shows a positive correla­
tion between histologic liver damage and stiff­
ness.17,18 This technique has been validated for 
most hepatic diseases and has reduced the num­
ber of liver biopsies performed, along with the oc­
currence of possible complications such as bleed­
ing, abdominal pain, or peritonitis.
Currently, effective methods for the diagno­
sis of FALD and the main factors influencing 
the degree of liver fibrosis are popular research 
areas. The aim of our study was to evaluate, in 
a long ­term follow ­up, the degree of LS using 
SWE among adult patients who had undergone 
the Fontan procedure and to investigate the re­
lationship between patient characteristics (such 
as medical history, laboratory parameters, and 
echocardiographic data) and the degree of LS in 
these patients. Patients were followed for a min­
imum of 6 months (up to 24 months).
PATIENTS AND METHODS Patients This retro­
spective study included 59 adult patients with 
Fontan circulation, followed at  the Depart­
ment of Cardiac and Vascular Diseases, Insti­
tute of Cardiology in Kraków, Poland, between 
2015 and 2017. The exclusion criteria were as 
follows: current infection, inflammation, major 
trauma, pregnancy, diabetes, and history of al­
cohol abuse.
Study protocol The following information was 
recorded for each patient in the study: type of 
cardiac malformation, history of cardiac opera­
tions, age at the time of surgical repair, type of 
systemic ventricle, comorbidities (protein ­losing 
enteropathy, arrhythmia), laboratory tests, ox­
ygen saturation, New York Heart Association 
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Echocardiography The mean SVEF was 51.4% 
(9.5%). Atrioventricular valve regurgitation was 
mild in 28 patients (47%); moderate, in 16 (27%); 
and severe, in 3 (7%). In 11 patients (19%), atrio­
ventricular valve regurgitation was minimal. Fen­
estration was seen in 30 patients (51%). Other 
echocardiographic findings included: left ven­
tricular noncompaction (1 patient), coarctation 
of the aorta (1 patient), coronary right ventricu­
lar fistula (1 patient), pericardial effusion (2 pa­
tients), aortic aneurysm (1 patient), and aortic 
valve regurgitation (21 patients: moderate in 
9 patients and mild in 12 patients).
Biochemical test results Laboratory test results 
are presented in TABLE 2. Hepatitis serology was 
positive in 6 patients (4 had chronic hepatitis B 
and 2 had chronic hepatitis C). Among liver pa­
rameters, elevated indirect bilirubin levels were 
the most frequent abnormality (80% of patients). 
High GGPT levels and low total platelet count 
were observed in 68% of patients. The INR was 
increased in 18 patients (42% of patients who 
were not receiving therapy with vitamin K an­
tagonists). Reduced total protein levels were ob­
served in 12% of patients, and abnormal albu­
min levels, in 8%. Protein ­losing enteropathy 
was observed in 9 patients (15%). Hepatic fibro­
sis scores, based on laboratory test results such 
as the AST/ALT ratio, platelet count, APRI score, 
Forns index, and FIB ­4 score, are also shown in 
TABLE 2.
Liver disease severity Thirteen patients under­
went an upper endoscopy, of whom 7 patients 
(54%) had varices and 7 (54%) had gastric or 
duodenal erosions or features of portal gastrop­
athy. Furthermore, at least 16 patients (30%) 
had features of portal hypertension according 
to the VAST scale (score ≥2) (TABLE 3). Accord­
ing to the Child–Pugh scale of liver cirrhosis se­
verity, 40 patients (78%) were in class A; 10 pa­
tients (20%), in class B; and 1 patient (2%) in 
class C. The median MELD ­XI score was 9.7 (IQR, 
1–19). Moreover, 2 patients were diagnosed with 
hepatocellular carcinoma.
Abdominal ultrasonography Abdominal ultraso­
nography was performed in 44 patients. Hepa­
tomegaly was present in 17 patients (43%), and 
splenomegaly, in 21 (48%). Increased echogenici­
ty was observed in 14 patients (32%), and liver 
surface nodularity, in 19 (44%). In 11 patients 
(25%), liver heterogeneity was shown.
 Shear wave elastography of the liver Shear wave 
elastography was performed in 54 patients. 
The median LS was 9.1 kPa (IQR, 3.9–18.5 kPa). 
Five of these patients (9%) had LS stage 1 (F1); 
14 (26%), stage 2 (F2); 28 (52%), stage 3 (F3); 
and 7 (13%), stage 4 (F4).
The  analysis of laboratory parameters in 
terms of LS (group 1 vs group 2) showed that 
patients with stages F3 and F4 had higher AST 
Statistical significance was set at a P value of 
less than 0.05. Statistica version 13 (StatSoft 
Inc., Tulsa, Oklahoma, United States) was used 
to analyze the data.
RESULTS Patient characteristics A  total of 
59 adult patients who had undergone the Fon­
tan procedure (median age, 23  years [IQR, 
18–46 years]; women, 37%) were included in 
the study. The median age of patients at the time 
of surgery was 4 years (IQR, 1–16 years), and 
the median time after surgery was 18 years (IQR, 
7–34 years). Baseline characteristics of patients 
are presented in TABLE 1.
Two patients died during the follow ­up (the 
first patient due to heart failure, and the second, 
due to heart failure with concomitant hepatocel­
lular carcinoma).
TABLE 1 Baseline characteristics of patients after the Fontan procedure
Variable Patients (n = 59)
Anatomic diagnosis, n (%)
Tricuspid atresia 14 (35)
Pulmonary stenosis / TGA 13 (22)
Double outlet right ventricle with left ventricular hypoplasia 2 (3)
Right ventricular hypoplasia 39 (64)
Hypoplastic left heart syndrome 5 (7)
Double ‑inflow left ventricle 1 (2)
Common atrioventricular canal 1 (2)
Ventricle type, n (%)
Left ventricle 47 (80)
Right ventricle 12 (20)
Type of Fontan procedure, n (%)
Atriopulmonary connection 4 (7)
Total cavopulmonary connection 55 (93)
NYHA functional class, n (%)
I 10 (17)
II 42 (71)
III 7 (12)
IV 0
Saturation, %, mean (SD) 90.3 (6.5)
Medications, n (%)
ASA 40 (68)
VKA 12 (22)
Enoxaparin 6 (10)
β ‑Blocker 8 (14)
ACEI 8 (14)
ARB 2 (3)
MRA 13 (22)
Diuretics 6 (10)
Sildenafil 6 (10)
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitors; ARB, angiotensin 
receptor blocker; ASA, acetylsalicylic acid; NYHA, New York Heart Association; MRA, 
mineralocorticoid receptor antagonist; TGA, transposition of great arteries; VKA, 
vitamin K antagonist
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TABLE 2 Patient characteristics and comparison of biochemical parameters and noninvasive liver fibrosis scores 
between patients with stages F1 and F2 of liver fibrosis and those with stages F3 and F4 1 and 2
Variable   Total value
  (n = 59)
METAVIR stage P value
 F1 and F2
 (n = 20)
F3 and F4
(n = 34)
Clinical features
Age, y 24.5 (18–46)  23 (18–46) 23(18–40) 0.85
Age at procedure, y 4.9 (1–16)  4.5 (1–16) 4 (1–16) 0.59
Time after procedure, y 18 (7–34)  18 (7–32) 18 (11–34) 0.9
Saturation, % 92 (68–98)  91 (82–98) 83 (68–98) 0.61
SVEF, %, mean (SD) 51.4 (9.5)  52.1 (11.7) 50.9 (8.7) 0.14
Hepatitis B, n (%) 4 (7%)  1 (5%) 3 (8%) –
Hepatitis C, n (%) 2 (3%)  1 (5%) 1 (3%) –
Laboratory parameters
NT ‑proBNP, ng/ml  130 (23–5539) 119 (23–3184) 130 (35–1794) 0.82
RBC, × 106/µl, mean (SD)  5.6 (0.5) 5.5 (0.7) 5.7 (0.4) 0.53
Hemoglobin, g/dl, mean (SD)  16.4 (1.8) 16.3 (1.9) 16.8 (1.7) 0.39
Hematocrit, %, mean (SD)  48.6 (4.7) 48 (5) 49.6 (4.3) 0.30
Platelets, × 103/µl  154.5 (59–322) 173 (102–281) 137 (59–322) 0.02
AST, IU/l  25.4 (16–60) 22 (16–60) 28.5 (16–41) 0.005
ALT, IU/l  27 (11–67) 24.5 (11–67) 28.5 (11–51) 0.08
GGTP, IU/l  78 (25–255) 59 (25–170) 84 (28–255) 0.008
Total bilirubin, µmol/l  20.5 (3.5–135) 19.7 (9.5–61.6) 20.5 (3.5–135) 0.35
α ‑Fetoprotein, ng/ml  2.5 (0.8–18.6) 2.5 (1–13) 2.9 (0.8–18.6) 0.68
ALP, IU/l  84 (38–364) 79 (38–121) 83 (47–364) 0.75
Total protein, g/l, mean (SD)  72.8 (9.9) 72.7 (8.1) 72.4 (11.4) 0.69
Albumin, g/l  43.1(20.5–50.2) 43 (31.5–50) 43 (20.5–48.7) 0.72
Liver fibrosis scores
AST/ALT ratio  0.95 (0.5–2) 0.9 (0.5–2) 1 (0.6–1.7) 0.84
APRI  0.4 (0.2–1.5) 0.3 (0.2–0.6) 0.5 (0.2–1.5) 0.003
Forns index, mean (SD)  4.5 (1.9) 3.9 (1.6) 4.8 (1.9) 0.048
FIB ‑4 score  0.8 (0.3–3.2) 0.6 (0.3–1.8) 0.9 (0.3–3.2) 0.02
MELD ‑XI score  9.7 (1–19) 9.1 (1–15) 10 (1.1–19) 0.13
Vascular Doppler
MPV diameter, mm, mean (SD)    10 (1.9) 10.8 (1.9) 10.7 (1.9) 0.99
Splenic vein diameter, mm    8 (5–13) 8 (6–10) 8 (5–12) 0.56
Vd, cm/s, mean (SD)    16 (5.4) 14.2 (4.1) 17 (5.9) 0.12
Vs, cm/s    30 (18–47) 30 (18–47) 30 (19.8–42) 0.30
Vs/Vd    2 (1.2–4) 2 (1.6–2.7) 2 (1.2–4) 0.52
Data are presented as median (IQR) unless stated otherwise.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; APRI, aspartate transaminase ‑to ‑platelet ratio 
index; AST, aspartate transaminase; AST/ALT ratio, ratio of aspartate transaminase to alanine transaminase; FIB ‑4, 
fibrosis ‑4; GGTP, ‑glutamyl transpeptidase; MELD ‑XI, Model For End ‑stage Liver Disease Excluding International 
Normalized Ratio; MPV, main portal vein; NT ‑proBNP, N ‑terminal fragment of the prohormone brain natriuretic peptide; 
RBC, red blood cells; SVEF, single ventricular ejection fraction; Vd, diastolic velocity; Vs, systolic velocity
TABLE 3 Features of portal hypertension in the study group
VAST scale Number/total number (%) of patients
Varices 7/13 (54)
Ascites 6/59 (10)
Splenomegaly 21/44 (48)
Thrombocytopenia, <150 × 103/µl 25/59 (42)
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diameter was 8 mm (IQR, 5–13 mm). The medi­
an systolic ­to ­diastolic velocity ratio was 2.0 (1.2–
4). The MPV and splenic vein diameters did not 
differ between groups. Three patients (7%) had 
a planar spectrum of the MPV flow.
We did not reveal any correlations between LS 
and splenic and MPV diameters. In addition, no 
correlation was observed between the MPV di­
ameter and systolic ­to ­diastolic velocity ratio. 
The splenic vein diameter negatively correlated 
with the platelet count (rs = –0.5). No significant 
correlation was seen between vascular Doppler pa­
rameters and other clinical features (type of sur­
gery, ventricular morphology, time after the Fon­
tan procedure, age at surgery, SVEF, or atrioven­
tricular valve regurgitation).
levels compared with patients with stages F1 and 
F2 (P = 0.01). Also, GGTP levels and platelet count 
were different between groups (P = 0.01 and P = 
0.02, respectively). The comparison of other com­
mon liver parameters (ALT, ALP, total bilirubin, 
α ­fetoprotein, and total protein and albumin), he­
matologic parameters (red blood cell count, hemo­
globin, hematocrit), creatinine, and NT ­proBNP, 
did not show significant differences between 
groups. We also assessed the differences in liver 
fibrosis scores (AST/ALT ratio, APRI, FIB ­4, score, 
and Forns index) between groups 1 and 2 (TABLE 2). 
The APRI, FIB ­4 score, and Forns index were signif­
icantly higher in group 2 than in group 1 (TABLE 2).
Vascular Doppler Vascular Doppler was per­
formed in 41 patients. The mean (SD) MPV diam­
eter was 10 (1.9) mm, and the median splenic vein 
FIGURE 1 Correlation 
between liver stiffness 
and aspartate 
transaminase ‑to ‑platelet 
ratio index (APRI) in 
patients after the Fontan 
procedure.
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20FIGURE 2 Correlation 
between liver stiffness 
and fibrosis ‑4 (FIB‑4) 
score in patients after 
the Fontan procedure
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the 5 ­year survival rate, 35%. Considering that 
hepatocellular carcinoma is associated with high 
mortality, FALD may be one of the major determi­
nants of mortality in adult patients after the Fon­
tan procedure.
Time after the Fontan procedure was report­
ed as a possible factor influencing the degree of 
liver fibrosis.8,12,26 This is supported by our cur­
rent study, which showed that LS and liver fibro­
sis are strongly related to time after the Fontan 
procedure. These findings are in line with previ­
ous observations by Goldberg et al.12 Our study 
also showed that the patient age at the time of 
the Fontan procedure is another possible factor 
influencing liver fibrosis. Duorsola et al27 demon­
strated that LS increased rapidly after total cavo­
pulmonary connection. This could be a result of 
the new hemodynamic status immediately after 
the total cavopulmonary connection, with a dis­
proportion between liver outflow and portal flow, 
which is not proportionally reduced.
Of note, our findings disagree with those of 
Johnson et al,28 who showed that increased pa­
tient age at the time of the Fontan procedure 
correlated with a higher grade of sinusoidal fi­
brosis. It has to be stated, however, that their 
study was a retrospective postmortem analysis, 
with a median interval of 14 days from the Fon­
tan procedure to death, limited to a small group 
of patients who underwent the Fontan proce­
dure at an advanced age and who had predomi­
nantly atriopulmonary Fontan connections. On 
the other hand, several studies demonstrated 
that LS increases even before the Fontan proce­
dure, after the Glenn procedure, or directly after 
the Fontan procedure.29,30 The chronic low pre­
load of a univentricular heart results in remodel­
ing, reduced compliance with increasing diastol­
ic pressure, low ventricular filling leading to car­
diac output decrease, and liver hypoperfusion.31 
Correlation between liver stiffness and biochemical find-
ings The degree of LS correlated with the plate­
let count (rs = –0.33), GGTP levels (rs = 0.37), 
and AST levels (rs = 0.33). Furthermore, LS was as­
sociated with higher APRI (rs = 0.38), FIB ­4 score 
(rs = 0.35), and Forns index (rs = 0.29). The cor­
relations are presented in FIGURES 1–3. Other clini­
cal parameters, including age, age at procedure, 
time after the Fontan procedure, single ventric­
ular morphology, SVEF, degree of atrioventric­
ular valve regurgitation, and biochemical liver 
test results did not correlate with LS as assessed 
by SWE.
The canonical correlation analysis was used to 
assess the effect of individual factors on LS and 
thrombocytopenia. We established a significant 
model that included age of the patient at the time 
of the Fontan procedure, time after Fontan pro­
cedure, and SVEF. The analysis indicated that LS 
and thrombocytopenia were strongly related to 
time after the Fontan procedure, with a loading 
vector of 0.797. Increased LS and thrombocy­
topenia were associated with age at the Fontan 
procedure, with a loading vector of –0.434, and 
SVEF, with a loading vector of –0.49.
DISCUSSION Our study was designed to evaluate 
liver status and the degree of LS, using noninva­
sive methods in 59 adult patients after the Fontan 
procedure. One of the most important findings is 
that all patients who had undergone the Fontan 
procedure had developed various stages of LS in 
a long ­term follow ­up, as assessed by SWE. Fur­
thermore, 65% of patients with stages F3 or F4 of 
fibrosis had an advanced stage of LS 20 years af­
ter the procedure, as compared with 35% of pa­
tients with stages F1 or F2. Moreover, 13% of 
patients were diagnosed with hepatic cirrhosis, 
while 2 patients, with hepatocellular carcinoma. 
Pundi et al10 reported that the 1 ­year survival 
rate of patients with liver cirrhosis was 57%, and 
FIGURE 3 Correlation 
between liver stiffness 
and Forns index in 
patients after the Fontan 
procedure
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the best predictor of advanced liver damage. Ad­
ditionally, the MELD ­XI score can be used to as­
sess eligibility for liver transplant.18 In our study, 
patients with an advanced stage of hepatic fibro­
sis (F3, F4) had higher MELD ­XI scores than pa­
tients with stages F1 and F2; however, the differ­
ence was not significant.
Indications for heart transplantation alone or 
a combined heart and liver transplant are cur­
rently widely debated. Recent studies have sug­
gested that a combined heart and liver transplant 
can be considered in the treatment of patients 
with failing Fontan circulation. Furthermore, ad­
vanced liver fibrosis and cirrhosis should not be 
a contraindication to heart transplant in these 
patients.38 Conversely, Lin et al21 reported that 
double transplant in patients with compensated 
liver disease may be too aggressive. Importantly, 
other studies documented the possibility of liv­
er function improvement or even liver fibrosis 
resolution when heart function is restored (af­
ter heart transplant) in patients with a cardiac 
origin of fibrosis.39
Further studies in a population with function­
ally univentricular heart are needed to better se­
lect candidates for heart transplant or combined 
heart and liver transplant. Moreover, a personal­
ized approach with innovative surgical and med­
ical methods is required to provide optimal care 
to this patient group.40
Study limitations Our study has several limita­
tions. The study group was limited, and the pop­
ulation was heteroge neous regarding their ini­
tial diagnoses and the type of Fontan surgery. 
Furthermore, the study was performed in a sin­
gle center; however, to the best of our knowl­
edge, the study includes the largest number of 
adult patients after the Fontan procedure in Pol­
ish population. Finally, the liver fibrosis stage was 
assessed noninvasively only due to the high risk 
of liver biopsy complications. Only 2 patients 
in our cohort with a suspicion of hepatocellular 
carcinoma underwent liver biopsy. In our study, 
we used SWE to estimate the LS and liver fibro­
sis degree as well as to validate the utility of LS 
scores derived from the available clinical param­
eters. We proved the usefulness of these scores as 
noninvasive markers of the liver status in routine 
follow ­up. It has been widely recognized, howev­
er, that the noninvasive methods for LS estima­
tion have their inherent limitations. For exam­
ple, transient elastography in FALD is problem­
atic because of other causes of hepatic stiffness, 
for example, vascular congestion. Nevertheless, 
a real ­time 2 ­dimensional SWE can monitor liver 
fibrosis by measuring tissue elasticity (ie, elastic 
modulus). Moreover, SWE is more accurate than 
transient elastography in detection of significant 
fibrosis. Finally, Kutty et al19 reported that SWE 
showed a positive correlation between histolog­
ical liver damage and rigidity.
This is in line with our findings, as we demon­
strated that the SVEF is another significant fac­
tor related to the stage of LS.
The diagnosis and assessment of FALD is dif­
ficult, because the disease frequently remains as­
ymptomatic over a long period of time. Moreover, 
our study showed that most of the biochemical 
markers commonly used in clinical practice did 
not correlate with LS, with the exception of AST, 
GGTP, and platelet count. Recent studies have 
reported that patients with Fontan circulation 
have abnormal liver parameters and coagulation 
factors.26,32 According to some authors, FALD 
is mostly associated with normal or only mildly 
increased levels of liver parameters.11,33 A multi­
center study by Carter ­Kent et al34 revealed that 
elevated AST levels were the only biochemical pa­
rameter associated with the degree of liver fibro­
sis. A study by Lindsay et al9 showed that AST lev­
els were significantly higher in patients with ad­
verse liver outcomes (including symptomatic syn­
thetic hepatic dysfunction, hepatocellular carcino­
ma or adenomatosis, and hepatorenal syndrome 
requiring liver transplant), when compared with 
the subgroup without adverse liver outcome.
A platelet count of less than 150 × 103/µl is 
a hallmark of hypersplenism, usually the first 
and sometimes the only feature of portal hyper­
tension. Furthermore, a serial decrease in plate­
let count may correlate with hepatic fibrosis, and 
even a slight decrease in platelet count may be 
significant enough to diagnose liver fibrosis and 
hypersplenism.4,35 In our study, thrombocytope­
nia strongly correlated with time after the Fon­
tan procedure and SVEF.
In our study, 16 patients (30%) had features 
of portal hypertension according to the VAST 
scale. As described by Elder et al,13 patients with 
features of portal hypertension, such as varices 
and ascites, have a 9 ­fold higher risk of adverse 
events such as death, requirement for transplan­
tation, or hepatocellular carcinoma.
Due to the  invasiveness of liver biopsies, 
a number of fibrosis scores were created as a non­
invasive method for liver fibrosis assessment. 
They are currently used in clinical practice to di­
agnose and assess liver fibrosis in adult patients 
with hepatitis B and C, alcoholic fatty disease, 
and nonalcoholic fatty liver disease.19,36 Fibrosis 
scores are based on biochemical and clinical pa­
rameters widely used in clinical practice, such as 
the AST/ALT ratio, APRI, Forns index, and FIB­
­4 score. Although these parameters have not 
yet been validated in patients with FALD, there 
are several studies documenting the use of nov­
el hepatic fibrosis scores.13,18,37 However, most 
of those studies were conducted on a pediatric 
population. Our study showed that the stage of 
LS, as measured by SWE, is associated with high­
er liver fibrosis scores. Patients with higher LS 
(stage F3 or F4) had significantly higher APRI, 
FIB ­4 score, and Forns index, when compared 
with patients in stages F1 and F2. Interestingly, 
Téllez et al18 demonstrated that the Forns index is 
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Conclusions Our study revealed that adult patients 
after the Fontan procedure tend to develop liver dys­
function in a long ­term follow ­up. The pathomech­
anism of liver impairment is complex and multifac­
torial. Time after surgery, age at the time of the pro­
cedure, and SVEF are strongly related to the degree 
of LS as assessed by SWE. Moreover, SWE and liv­
er fibrosis scales based on biochemical and clinical 
parameters such as the APRI, Forns index, and FIB­
­4 score may be helpful in assessing the severity of 
liver fibrosis. Therefore, they should be considered 
in regular noninvasive hepatic monitoring to diag­
nose FALD and initiate early treatment in patients 
with functionally univentricular heart.
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